Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | STAT6 | P42226 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6672740 | 1.00 | TUBB1 (0.44) | TUBB1NPSR1MMP13MAPTUSP2 | |
| SCHEMBL6672739 | 1.00 | TUBB1 (0.44) | TUBB1NPSR1MMP13MAPTUSP2 | |
| SCHEMBL6670110 | 1.00 | TUBB1 (0.44) | TUBB1NPSR1MMP13MAPTUSP2 | |
| SCHEMBL6806057 | 1.00 | TUBB1 (0.44) | TUBB1NPSR1MMP13MAPTUSP2 | |
| SCHEMBL6688285 | 0.91 | TUBB1 (0.37) | TUBB1NPSR1USP2 | |
| SCHEMBL6688291 | 0.91 | TUBB1 (0.37) | TUBB1NPSR1USP2 | |
| SCHEMBL6686823 | 0.88 | TUBB1 (0.44) | TUBB1MMP2MMP3 | |
| SCHEMBL13682586 | 0.85 | TUBB1 (0.60) | TUBB1MMP13STAT6AAK1 | |
| SCHEMBL57529 | 0.85 | TUBB1 (0.60) | TUBB1MMP13STAT6AAK1 | |
| SCHEMBL14210168 | 0.85 | TUBB1 (0.60) | TUBB1MMP13STAT6AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | TUBB1 199/4885NPSR1 1263/4885MMP13 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.